Milestone Pharmaceuticals Inc
NASDAQ:MIST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hyatt Hotels Corp
NYSE:H
|
US |
Milestone Pharmaceuticals Inc
Revenue
Milestone Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Milestone Pharmaceuticals Inc
NASDAQ:MIST
|
Revenue
$1.5m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Revenue
$10.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
0%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Revenue
CA$278.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
43%
|
|
|
Cronos Group Inc
TSX:CRON
|
Revenue
$146.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Revenue
CA$450.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
18%
|
CAGR 10-Years
84%
|
|
Milestone Pharmaceuticals Inc
Glance View
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 29 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate is etripamil. The etripamil is a novel, potent and short-acting calcium channel blocker that has been designed rapid-onset nasal spray, which is self-administered by patients. The firm is developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF) and rapid ventricular rate, and other cardiovascular indications.
See Also
What is Milestone Pharmaceuticals Inc's Revenue?
Revenue
1.5m
USD
Based on the financial report for Dec 31, 2025, Milestone Pharmaceuticals Inc's Revenue amounts to 1.5m USD.
What is Milestone Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
-32%
The average annual Revenue growth rates for Milestone Pharmaceuticals Inc have been -32% over the past three years .
